MARIXINO 10 MG TBL FLM 98

What is the maximum co-payment for MARIXINO?

If the insurance company contributes, the maximum co-payment is 2 054,58 Kč. The maximum pharmacy price is 2 813,64 Kč. A pharmacy may provide the medicine for a lower price, but not for a higher price.

Does the medicine have reimbursement from public health insurance?

Yes, but the reimbursement conditions (reporting limit) have not been set.

Does MARIXINO have a counted co-payment set?

No, this medicine has no counted co-payment.

How much does the insurance company pay for one dispensed reimbursed pack?

759,06 Kč.

Does the insurance company pay a higher amount in some cases?

No, the medicine has no increased reimbursement.

Does the medicine have an indication restriction?

Memantin je hrazen u pacientů s potvrzenou diagnózou demence u Alzheimerovy choroby u střední a těžké demence s objektivně prokázaným postižením kognitivních funkcí a aktivit denního života, u nichž je zajištěno správné užívání léčby. Léčba je dále hrazena, dokud je prokazatelný příznivý efekt na kvalitu života (hodnoceno komplexně – kognitivní funkce, neuropsychiatrické příznaky, aktivity denního života), pravidelně hodnocený v intervalu 3-6 měsíců dle stavu. Memantin není hrazen u terminální demence.

Is it available without a medical prescription?

No, the medicine cannot be obtained without a prescription.

Which medical specialist may prescribe MARIXINO?

Prescription is not conditional on a medical specialization.

What is the composition of MARIXINO?

Memantin-hydrochlorid (10 mg), memantin (8,31 mg), monohydrát laktosy, neznámá látka s kódem 3755, koloidní bezvodý oxid křemičitý, ointmentek, magnesium-stearát, neznámá látka s kódem 16114, natrium-lauryl-sulfát, polysorbát 80, neznámá látka s kódem 4105, simetikon. More information about the composition can be found in the SPC, section 6.1.

Where can I find information about correct use of the medicine?

Which medicines are similar to MARIXINO?

The medicine belongs to ATC group N06DX01 – MEMANTIN. Medicines with the same active substance can be found here.

Who manufactures MARIXINO?

Krka, d.d., Novo mesto, Novo mesto (SLO)

Is the medicine in shortage?

The latest report from the manufacturer is from 3. 6. 2025. Production was terminated with effect from 17. 9. 2025. The manufacturer lists medicines with the following code as a potential substitute: